Impact of human immunodeficiency virus infection on mortality of patients who acquired healthcare associated-infection in critical care unit

Carregando...
Imagem de Miniatura
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Citação
MEDICINE, v.98, n.23, article ID e15801, 8p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
To evaluate 30-day mortality in human immunodeficiency virus (HIV) and non-HIV patients who acquired a healthcare-associated infection (HAI) while in an intensive care unit (ICU), and to describe the epidemiological and microbiological features of HAI in a population with HIV. This was a retrospective cohort study that evaluated patients who acquired HAI during their stay in an Infectious Diseases ICU from July 2013 to December 2017 at a teaching hospital in Brazil. Data were obtained from hospital infection control committee reports and medical records. Statistical analysis was performed using SPSS and a multivariate model was used to evaluate risk factors associated with 30-day mortality. Epidemiological, clinical, and microbiological characteristics of HAI in HIV and non-HIV patients and 30-day mortality were also evaluated. Among 1045 patients, 77 (25 HIV, 52 non-HIV) patients acquired 106 HAI (31 HIV, 75 non-HIV patients). HIV patients were younger (45 vs 58 years, P=.002) and had more respiratory distress than non-HIV patients (60.0% vs 34.6%, P=.035). A high 30-day mortality was observed and there was no difference between groups (HIV, 52.0% vs non-HIV, 54.9%; P=.812). Ventilator-associated pneumonia (VAP) was more frequent in the HIV group compared with the non-HIV group (45.2% vs 26.7%, P=.063), with a predominance of Gram-negative organisms. Gram-positive agents were the most frequent cause of catheter associated-bloodstream infections in HIV patients. Although there was a high frequency of HAI caused by multidrug-resistant organisms (MDRO), no difference was observed between the groups (HIV, 77.8% vs non-HIV, 64.3%; P=.214). Age was the only independent factor associated with 30-day mortality (odds ratio [OR]: 1.05, 95% confidence interval [CI]: 1.01-1.1, P=.017), while diabetes mellitus (OR: 3.64, 95% CI: 0.84-15.8, P=.085) and the Sequential Organ-Failure Assessment (SOFA) score (OR: 1.16, 95% CI: 0.99-1.37, P=.071) had a tendency to be associated with death. HIV infection was not associated with a higher 30-day mortality in critical care patients with a HAI. Age was the only independent risk factor associated with death. VAP was more frequent in HIV patients, probably because of the higher frequency of respiratory conditions at admission, with a predominance of Gram-negative organisms.
Palavras-chave
critical care, health care-associated infections, human immunodeficiency virus infection, infection control, infectious diseases, intensive care units
Referências
  1. Akgun KM, 2013, CRIT CARE MED, V41, P1458, DOI 10.1097/CCM.0b013e31827caa46
  2. Amancio FF, 2012, INT J STD AIDS, V23, P692, DOI 10.1258/ijsa.2012.011389
  3. [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST
  4. Bonnet F, 2002, HIV Med, V3, P195, DOI 10.1046/j.1468-1293.2002.00117.x
  5. Casalino E, 2004, AIDS, V18, P1429, DOI 10.1097/01.aids.0000131301.55204.a7
  6. Cobos-Trigueros N, 2014, EUR J CLIN MICROBIOL, V33, P611, DOI 10.1007/s10096-013-1995-5
  7. Cofsky R, 2002, INFECT CONT HOSP EP, V23, P106
  8. Croda J, 2009, CRIT CARE MED, V37, P1605, DOI 10.1097/CCM.0b013e31819da8c7
  9. Declercq S, 2015, INFECT DIS-NOR, V47, P611, DOI 10.3109/23744235.2015.1033002
  10. Fan X, 2015, C55 HIV ASS LUNG DIS, pA4718
  11. Giske CG, 2008, ANTIMICROB AGENTS CH, V52, P813, DOI 10.1128/AAC.01169-07
  12. Gould CV, 2017, HEALTHC INFECT CONTR, P1
  13. Gupta A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022730
  14. Hospitals US, 2007, PUBLIC HLTH REP, V122, P160
  15. Huang L, 2006, NEW ENGL J MED, V355, P173, DOI 10.1056/NEJMra050836
  16. Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221
  17. Maartens G, 2014, LANCET, V384, P258, DOI 10.1016/S0140-6736(14)60164-1
  18. Magill SS, 2014, NEW ENGL J MED, V370, P1198, DOI 10.1056/NEJMoa1306801
  19. Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x
  20. MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402
  21. Medrano J, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0475-3
  22. Morris A, 2002, AM J RESP CRIT CARE, V166, P262, DOI 10.1164/rccm.2111025
  23. Narasimhan M, 2004, CHEST, V125, P1800, DOI 10.1378/chest.125.5.1800
  24. O'Grady NP, 2011, GUIDELINES PREVENTIO, V39
  25. Padoveze MC, 2002, AM J INFECT CONTROL, V30, P346, DOI 10.1067/mic.2002.125220
  26. Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
  27. Panis C, 2009, BRAZ J MICROBIOL, V40, P155, DOI [10.1590/S1517-83822009000100027, 10.1590/S1517-838220090001000027]
  28. Pathak V, 2012, CLIN MED RES, V10, P57, DOI 10.3121/cmr.2011.987
  29. Petrosillo N, 2002, CLIN INFECT DIS, V34, P677, DOI 10.1086/338813
  30. Petrosillo N, 1999, AIDS, V13, P599, DOI 10.1097/00002030-199904010-00009
  31. Reinheimer C, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2286-z
  32. Siegel JD, 2007, AM J INFECT CONTROL, V35, pS165, DOI 10.1016/j.ajic.2007.10.006
  33. Tacconelli E, 2000, J HOSP INFECT, V44, P186, DOI 10.1053/jhin.1999.0687
  34. Tchakoute CT, 2017, REV RECENT CLIN TRIA, V12, P44, DOI 10.2174/1574887111666160906094140
  35. WACHTER RM, 1986, AM REV RESPIR DIS, V134, P891, DOI 10.1164/arrd.1986.134.5.891
  36. Wiewel MA, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1469-0
  37. World Health OrganizationHealth care-associated infections Fact sheet, 2015, WHO EP IMP DEM CURR, P4, DOI 10.1007/S13398-014-0173-7.2